Teva Prepares To Launch LAI Risperidone After US Approval
MedinCell-Partnered Schizophrenia Treatment Uzedy Has Now Been Approved By US FDA
Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.
You may also be interested in...
Teva’s commercial interests in North America will soon be under new leadership after the firm announced that Sven Dethlefs would leave the company in mid-November. The firm has looked to the branded sector for his replacement.
Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once-
With Teva continuing to report declining North American generics sales – albeit more than offset by increases in other territories and business units – the company has highlighted future targets in the US as it pushes forward with its new “pivot to growth” strategy.